Luye Pharma
Luye Pharma is a Hong Kong-listed specialty pharmaceutical company developing innovative drugs in oncology, CNS, and cardiovascular therapy using proprietary microsphere, liposome, and transdermal delivery platforms, with operations in 80+ countries and manufacturing across 8 global bases.
- Company typePublic
- Founded1994
- HeadquartersShanghai, China
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Luye Pharma does
Luye Pharma Group (HKEX: 02186.HK) is a Hong Kong-listed specialty pharmaceutical company founded in 1994 and headquartered in Yantai, Shandong Province, with secondary operations in Shanghai. A subsidiary of Luye Life Sciences Group, it generates the substantial majority of its roughly RMB 6.3 billion (~$870M USD) FY2025 revenue from innovative and generic drugs across three therapeutic franchises — oncology (Baituowei goserelin microsphere, Zanbijia lurbinectedin), CNS (ERZOFRI paliperidone palmitate in the US, Rykindo risperidone microsphere, Ruoxinin for depression, rivastigmine and rotigotine transdermal patches), and cardiovascular/diabetes/ophthalmology — with an OTC health and wellness tail. Approximately 50 approved products are sold in over 80 countries through self-operated commercial teams in China and the US, supplemented by distribution partnerships with Sinopharm and Enhua Pharma in China and international commercialization partners in Europe, Japan, and Southeast Asia.
Luye Pharma firmographics
Firmographics- Name
- Luye Pharma
- Legal name
- 绿叶制药集团有限公司 (Luye Pharma Group Co., Ltd.)
- Website
- https://luye.cn
- Company type
- Public
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Luye Pharma is a Hong Kong-listed specialty pharmaceutical company developing innovative drugs in oncology, CNS, and cardiovascular therapy using proprietary microsphere, liposome, and transdermal delivery platforms, with operations in 80+ countries and manufacturing across 8 global bases.
- Ownership category
- akta.pro rank
Luye Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Luye Pharma is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
Luye Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Revenue from sale of innovative drugs, generic drugs, and over-the-counter (OTC) health and wellness products across three segments: oncology, CNS (central nervous system), and cardiovascular. The company operates across 80+ countries including China, US, Europe, Japan, and emerging markets.
- New Product Commercialization: Revenue growth driven by commercialization of newly launched products including ERZOFRI® (paliperidone palmitate injectable suspension) in US, Rykindo® (risperidone long-acting microspheres), and other innovative drugs in China and global markets. New product revenue grew 56.8% year-over-year in 2025.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels1 record
Luye Pharma product offering
Product offeringCore offering
Luye Pharma is an international pharmaceutical company that researches, develops, manufactures, and commercializes innovative drugs across three core therapeutic areas: oncology, central nervous system (CNS) disorders, and cardiovascular diseases. The company operates advanced drug delivery technology platforms including microspheres, liposomes, and transdermal patches, and has a portfolio of approximately 50 approved products sold across 80+ countries through its 8 global manufacturing bases.
Product overview
Luye Pharma is an international pharmaceutical company dedicated to innovative drug R&D, manufacturing, and sales. The company focuses on three core therapeutic areas: anti-tumor chemotherapy drugs, central nervous system (CNS) innovative drugs, and biologics. Its advanced drug delivery technology platforms include microsphere, liposome, and transdermal delivery systems at international levels. The portfolio includes: CNS drugs such as ERZOFRI® (paliperidone palmitate monthly injection), Rykindo® (risperidone microsphere injection), and 若欣林® (for depression); oncology drugs including 百拓维® (goserelin microsphere) and 赞必佳® (lurbinectedin); biologic products like 博优景® (aflibercept) and 博优平® (dulaglutide); and transdermal patches including 利斯的明透皮贴剂 and 罗替高汀贴剂. The company has achieved 15 new product approvals across the US, China, Japan, and Europe between 2021-2025, with a robust pipeline including LY03015, LY03017, and LY03020 in CNS and various biologic candidates. Luye Pharma operates 8 global manufacturing bases and maintains an international GMP quality management system.
Differentiator
Problem solved
Functional benefit
Brands
- Rykindo (瑞可盈): Risperidone extended-release microsphere injection - treatment for schizophrenia, launched in US
- Erzofri (亿左福)
- 若欣林 (Ruoxinin)
- 百拓维 (Baituowei)
- 赞必佳 (Zanbijia)
- 博安生物 (Bo'an Biological)
Products and services
- ERZOFRI® (paliperidone palmitate extended-release suspension injection) Monthly injectable for schizophrenia treatment; the only paliperidone palmitate monthly injection in the US offering a 'first month one injection' dosing regimen. Launched in the US in April 2025.
- Rykindo® (risperidone extended-release microsphere injection) Long-acting injectable for schizophrenia treatment using microsphere drug delivery. Approved and launched in the United States.
- 若欣林® Ruoxinin (tolafrazine sustained-release tablets) China's first self-developed Class 1 innovative chemical drug for depression treatment. Included in China's national medical insurance with rapid market penetration and received Level 1A recommendation as first-line treatment in the 2025 China Depression Prevention and Treatment Guidelines.
- 百拓维® Baituowei (goserelin long-acting microsphere injection) The world's only currently marketed goserelin long-acting microsphere formulation for prostate cancer and breast cancer. Renewed in China's national medical insurance directory at the end of 2025 with multiplicative sales growth.
Quantifiable outcome
- New product revenue grew 56.8% in 2025
- +3 more outcomes
Companies that use Luye Pharma
Customer profileSegments3 records
Ideal customer profiles3 records
Luye Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Luye Pharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- Sinopharm Group & Sinopharm Shares (国药控股、国药股份)coreStrategic collaboration with Sinopharm Group and Sinopharm Shares to strengthen commercialization of Meimeixin® (米美欣®) and other products, leveraging Sinopharm's extensive distribution network across China to reach broader market coverage.
- Enhua Pharma (恩华药业)coreLuye Pharma granted exclusive commercialization rights to Enhua Pharma for three long-acting injectable antipsychotic products in mainland China. The partnership leverages Enhua's established hospital and clinic network to expand market penetration across all levels of medical institutions and retail terminals.
- Shang Pharmaceutical Holdings (上药控股)majorPartnership with Shang Pharmaceutical Holdings as part of Bo'an Bioscience subsidiary's global biological product expansion strategy.
- Jianyou Pharma (健友股份)majorPartnership with Jianyou Pharma as part of Bo'an Bioscience subsidiary's collaboration for global biological product expansion.
- Kexing Pharma (科兴制药)majorPartnership with Kexing Pharma as part of Bo'an Bioscience subsidiary's collaboration for global biological product expansion.
- Bo'an Bioscience (博安生物)coreBo'an Bioscience is a controlled subsidiary of Luye Pharma developing innovative biological drugs including BA1106 (anti-CD25 antibody for solid tumors), BA1302 (CD228 ADC), and other bispecific antibodies and cytokine fusion proteins in clinical development.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
Luye Pharma competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Luye Pharma social profiles
Digital presenceLuye Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Luye Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Luye Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Luye Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Luye Pharma M&A and investment
M&A and investmentM&A1 record
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Luye Pharma
What does Luye Pharma do?
Luye Pharma is an international pharmaceutical company that researches, develops, manufactures, and commercializes innovative drugs across three core therapeutic areas: oncology, central nervous system (CNS) disorders, and cardiovascular diseases. The company operates advanced drug delivery technology platforms including microspheres, liposomes, and transdermal patches, and has a portfolio of approximately 50 approved products sold across 80+ countries through its 8 global manufacturing bases.
Is Luye Pharma a public or private company?
Luye Pharma is a public company. It is classified as public and is currently operating.
When was Luye Pharma founded?
Luye Pharma was founded in 1994. It employs 5,001 to 10,000 people.
Where is Luye Pharma based?
Luye Pharma is headquartered in Shanghai, China, in the Asia region.
How does Luye Pharma make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are new Product Commercialization.
Does Luye Pharma have an API?
No public API is recorded for Luye Pharma.
What industry is Luye Pharma in?
Luye Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.